DNA damage detected with γH2AX induced by anticancer drugs on ovarian clear cell carcinoma
DNA damage detected with γH2AX induced by anticancer drugs on ovarian clear cell carcinoma
批准号:
22591864
负责人:
SUGIYAMA Toru
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2010
资助国家:
日本
项目状态:
已结题
起止时间:
2010 至 2012
中文摘要
采用组蛋白希斯顿H2 AX(γ H2 AX)磷酸化方法,比较卵巢透明细胞癌(CCC)、子宫体类腺瘤和宫颈鳞状细胞癌抗肿瘤药物诱导的DNA损伤的发生率和类型的差异.卵巢透明细胞腺癌(CCC):顺铂(CDDP)作用后,S期细胞DNA损伤频繁,G1期和G2/M期细胞周期阻滞,γ H2 AX无明显增加。两种细胞系对CDDP和卡铂(CBDCA)的敏感性不同。紫杉醇(PTX)的抗肿瘤作用是由G2/M期阻滞诱导的,与CBDCA联合治疗,诱导G2/M期细胞的DNA损伤,可能是有效的。这是日本首次以γ H2 AX为指标,通过关注细胞周期与DNA损伤之间的关系,评价抗癌药物的抗肿瘤活性的研究。免疫细胞化学方法用于 关于我们 本研究检测γ H2 AX,其即使在非常低的浓度下也能以高灵敏度指示DNA损伤。因此,一个有前途的方法,容易和快速地确定代理可能有效地对CCC。2.子宫体子宫内膜样腺癌:研究显示,药物治疗后,细胞系之间在DNA损伤与细胞周期特异性、诱导凋亡或衰老方面存在显著差异。多柔比星(DOX)对γ H2 AX的诱导作用不具有细胞周期特异性,其机制与另一种蒽环类DNA拓扑异构酶II抑制剂米托蒽醌相似,可能涉及其他因素调控的氧化性DNA损伤。用CDDP和5-氟尿嘧啶(5-FU)处理导致在S期细胞中优先磷酸化H2 AX,这与复制应激的诱导一致。表达wt p53的石川细胞的反应与其他细胞系相比是不同的。这些数据表明,用这些药物治疗类腺癌可能必须根据个体患者的情况进行定制。少
英文摘要
Differences in the incidences and types of DNA damage induced by antitumor agents for clear cell carcinoma (CCC) of the ovary, endometrioid adenocar cinoma of the uterine corpus, and squamous cell carcinoma of the cervix were determined using phosphory- lation of histon H2AX (γH2AX).1. Clear cell adenocarcinoma of the ovary (CCC): After administration of cisplatin(CDDP), DNA damage was frequent in S -phase cells, while cell-cycle arrest occurred in the G1 and G2/M phases and γH2AX did not increase in CDDP-resistant cells. Sensitivities to CDDP and carboplatin(CBDCA) differed between the two cell lines. The antitumor effect of paclitaxel(PTX) is induced by G2/M arrest, and combination treatment with CBDCA, inducing DNA damage in G2/M-phase cells, might be effective.This is the first study in Japan to evaluate the antitumor activity of anticancer agents by focusing on the relationship between the cell cycle and DNA damage using γH2AX as an indicator. The immunocytochemical method used in … More this study detects γH2AX, which indicates DNA damage even at very low concentrations and with high sensitivity. Therefore, a promising method of easily and rapidly identifying agents potentially effective against CCC. 2.Endometrioid adenocarcinoma of the uterine corpus: The study revealed significant differences among the cell lines in the effects of DNA damage vis-a-vis cell cycle phasespecificity, induction of apoptosis or senescence following drug treatment. doxorubicin (DOX) treatment showed little cell cycle specificity in terms of induction of γH2AX, and its mechanism, which is similar to another anthracycline DNA topoisomerase II inhibitor mitoxantrone, may involve oxidative DNA damage modulated by other factors. Treatment with CDDP and 5-fluorouracil (5-FU) led to phosphorylation of H2AXpreferentially in S -phase cells, consistent with the induction of replication stress. The response of Ishikawa cells expressing wt p53 was different compared to other cell lines. The data suggest that the treatment of endometrioid adenocarcinoma with these drugs may have to be customized to individual patients. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Second -Line Chemotherapy for Platinum- and Taxane-Resistant Epithelial Ovarian Cancer: Pegylated Liposomal Doxorubicin (PLD)
铂类和紫杉烷耐药性上皮性卵巢癌的二线化疗:聚乙二醇化脂质体阿霉素 (PLD)
DOI:
--
发表时间:
2012
期刊:
Irinotecan, and Combination Therapies at Lower Doses
影响因子:
--
作者:
[Hikita S, Yotsumoto F, Fumaki T, Horiuchi S, Sanui A, Miyata K, Nam SO, Tsujioka H, Ueda T, Shirota K, Yoshizato T, Maeda K, Ishikawa T, Okuno Y, Kuroki M, Mekada E, Miyamoto S, Toru Sugiyama.]
通讯作者:
Toru Sugiyama.
Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
使用盐酸伊立替康和奈达铂进行新辅助化疗,然后进行根治性子宫切除术治疗 Ib2 至 IIb 期宫颈鳞状细胞癌的 II 期研究:日本妇科肿瘤小组研究 (JGOG 1065)。
DOI:
10.3892/or.2012.1814
发表时间:
2012
期刊:
Oncology reports
影响因子:
4.2
作者:
[S. Yamaguchi, R. Nishimura, N. Yaegashi, K. Kiguchi, T. Sugiyama, T. Kita, K. Kubushiro, K. Kokawa, M. Hiura, K. Mizutani, Kaichiro Yamamoto, K. Takizawa]
通讯作者:
K. Takizawa
DOI:
10.1016/j.bmcl.2011.10.017
发表时间:
2011-12
期刊:
Bioorganic & medicinal chemistry letters
影响因子:
2.7
作者:
[T. Sugiyama;Y. Imamura;Yosuke Demizu;M. Kurihara;M. Takano;A. Kittaka]
通讯作者:
T. Sugiyama;Y. Imamura;Yosuke Demizu;M. Kurihara;M. Takano;A. Kittaka
DOI:
10.1186/1757-2215-5-16
发表时间:
2012-06-12
期刊:
Journal of ovarian research
影响因子:
4
作者:
[Takatori E, Shoji T, Kumagai S, Sawai T, Kurose A, Sugiyama T]
通讯作者:
Sugiyama T
DOI:
10.3892/ijo_00000589
发表时间:
2010-05
期刊:
International journal of oncology
影响因子:
5.2
作者:
[Ikeda M, Kurose A, Takatori E, Sugiyama T, Traganos F, Darzynkiewicz Z, Sawai T]
通讯作者:
Sawai T
共 30 条
Extended Multi-modal Kendo Terminology Lexicon Toward Developing an Electronic Learning Program for Kendo Beginners at Junior High Schools
-
批准号:24500695
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2012
-
负责人:SUGIYAMA Toru
-
依托单位:
Toward a creation of a multimodal database with kendo motion pictures and terminology of kendo developed as budo in the Japanese traditional culture
-
批准号:21500557
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.58万
-
财政年份:2009
-
负责人:SUGIYAMA Toru
-
依托单位:
Design and development of antigene agents based on strand invasion mechanism
-
批准号:20590099
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2008
-
负责人:SUGIYAMA Toru
-
依托单位:
Molecular mechanisms for chemoresistance to Paclitaxel in ovariancancer
-
批准号:19591941
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:SUGIYAMA Toru
-
依托单位:
A Digital Dictionary for the Physical and Spiritual Sports or the Japanese Traditional Budo and its Globalization
-
批准号:15500408
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.37万
-
财政年份:2003
-
负责人:SUGIYAMA Toru
-
依托单位:
Research on the effects of tamoxifen in rats with estrogen- and progesterone-receptor negative ovarian cancer.
-
批准号:14571595
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:2002
-
负责人:SUGIYAMA Toru
-
依托单位:
Second line chemotherapy for relapsed ovarian canser
-
批准号:11671662
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.79万
-
财政年份:1999
-
负责人:SUGIYAMA Toru
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于多模态磁共振的肾病认知障碍脑结构-功能耦联研究
-
批准号:JCZRLH202602116
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
LUC7L2剪接异常介导核仁应激在慢性肾脏病中的作用与机制
-
批准号:JCZRLH202602020
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于离子液体的植物叶蛋白质提取新方法及其在烟草赤星病研究中的应用
-
批准号:2026JJ60349
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:褚宏伟
-
依托单位:
口腔黏膜下纤维性变皮肤镜特征分析与大模型辅助诊断技术研究
-
批准号:2026JJ82650
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:苏维岚
-
依托单位:
基于AIGS的多模态胃肠肿瘤数智病理诊断机制与路径研究
-
批准号:2026JJ50598
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:王俊普
-
依托单位:
基于中性粒细胞胞外诱捕网形成探讨甲基莲心碱在尿酸性肾病中的作用机制
-
批准号:2026JJ80939
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:殷薇
-
依托单位:
肠道微生物代谢在早产儿坏死性小肠结肠炎发病机制中的作用研究
-
批准号:JCZRLH202601051
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
妊娠期糖尿病对胎盘铁转运的影响及机制研究
-
批准号:JCZRLH202601198
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
宫颈癌前病变演进机制与干预策略研究
-
批准号:JCZRLH202601526
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
水稻主要病虫害风险预警技术研究
-
批准号:2025JJ80277
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:黄晚华
-
依托单位: